tiprankstipranks
Ascendis Pharma (ASND)
NASDAQ:ASND
US Market
ASND
Ascendis Pharma
RESEARCH TOOLSreports

Ascendis Pharma (ASND) Stock Forecast & Price Target

693 Followers
See the Price Targets and Ratings of:

ASND Analyst Ratings

Strong Buy
13Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Ascendis
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ASND Stock 12 Month Forecast

Average Price Target

$293.77
▲(35.41% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Ascendis Pharma in the last 3 months. The average price target is $293.77 with a high forecast of $342.00 and a low forecast of $255.00. The average price target represents a 35.41% change from the last price of $216.95.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"150":"$150","343":"$343","198.25":"$198.3","246.5":"$246.5","294.75":"$294.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":342,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$342.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":293.77,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$293.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":255,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$255.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[150,198.25,246.5,294.75,343],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,242.09,249.7753846153846,257.46076923076924,265.1461538461539,272.83153846153846,280.5169230769231,288.2023076923077,295.8876923076923,303.57307692307694,311.2584615384616,318.94384615384615,326.6292307692308,334.3146153846154,{"y":342,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,242.09,246.06538461538463,250.04076923076923,254.01615384615386,257.9915384615385,261.9669230769231,265.9423076923077,269.9176923076923,273.89307692307693,277.86846153846153,281.84384615384613,285.8192307692307,289.7946153846154,{"y":293.77,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,242.09,243.08307692307693,244.07615384615386,245.06923076923078,246.06230769230768,247.0553846153846,248.04846153846154,249.04153846153847,250.0346153846154,251.02769230769232,252.02076923076925,253.01384615384615,254.00692307692307,{"y":255,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":156.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.48,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.16,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.11,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":201.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210.85,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":213.24,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.59,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242.09,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$342.00Average Price Target$293.77Lowest Price Target$255.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush Analyst forecast on ASND
Yun Zhong
Wedbush
Wedbush
$273
Buy
25.84%
Upside
Reiterated
03/17/26
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (NASDAQ: COGT) and Ascendis Pharma (NASDAQ: ASND)
TD Cowen Analyst forecast on ASND
Yaron Werber
TD Cowen
TD Cowen
$227→$325
Buy
49.80%
Upside
Assigned
03/16/26
Ascendis Pharma: Durable Endocrine Franchise Growth and Emerging Pipeline Upside Support Buy Rating
Morgan Stanley Analyst forecast on ASND
Maxwell Skor
Morgan Stanley
Morgan Stanley
$256
Buy
18.00%
Upside
Reiterated
03/16/26
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Stevanato Group (NYSE: STVN) and BioNTech SE (NASDAQ: BNTX)
Bank of America Securities Analyst forecast on ASND
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$260→$262
Buy
20.77%
Upside
Reiterated
03/16/26
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), BioMarin Pharmaceutical (NASDAQ: BMRN) and Ionis Pharmaceuticals (NASDAQ: IONS)
Jefferies Analyst forecast on ASND
Faisal Khurshid
Jefferies
Jefferies
$290
Buy
33.67%
Upside
Initiated
03/15/26
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Plus Therapeutics (PSTV)
Cantor Fitzgerald Analyst forecast on ASND
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
$254→$300
Buy
38.28%
Upside
Reiterated
03/04/26
Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK), Ascendis Pharma (NASDAQ: ASND) and Avalo Therapeutics (NASDAQ: AVTX)
Barclays Analyst forecast on ASND
Eliana Merle
Barclays
Barclays
$342
Buy
57.64%
Upside
Reiterated
03/03/26
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Incyte (NASDAQ: INCY) and Radnet (NASDAQ: RDNT)
Stifel Nicolaus Analyst forecast on ASND
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$325→$332
Buy
53.03%
Upside
Reiterated
03/02/26
Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG), Ascendis Pharma (NASDAQ: ASND) and Roche Holding AG (Other OTC: RHHVF)
Wells Fargo Analyst forecast on ASND
Derek Archila
Wells Fargo
Wells Fargo
$330
Buy
52.11%
Upside
Reiterated
03/02/26
Wells Fargo Remains a Buy on Ascendis Pharma (ASND)
Goldman Sachs Analyst forecast on ASND
Paul Choi
Goldman Sachs
Goldman Sachs
$250→$255
Buy
17.54%
Upside
Reiterated
03/02/26
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Intellia Therapeutics (NASDAQ: NTLA) and Immunic (NASDAQ: IMUX)
RBC Capital Analyst forecast on ASND
Luca Issi
RBC Capital
RBC Capital
$250→$275
Buy
26.76%
Upside
Reiterated
03/02/26
RBC Capital Sticks to Their Buy Rating for Ascendis Pharma (ASND)
Oppenheimer Analyst forecast on ASND
Leland Gershell
Oppenheimer
Oppenheimer
$246→$262
Buy
20.77%
Upside
Reiterated
02/12/26
Oppenheimer Keeps Their Buy Rating on Ascendis Pharma (ASND)
Evercore ISI Analyst forecast on ASND
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$317
Buy
46.12%
Upside
Reiterated
01/20/26
Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (NASDAQ: ACHC) and Ascendis Pharma (NASDAQ: ASND)
Wolfe Research Analyst forecast on ASND
Unknown Analyst
Wolfe Research
Not Ranked
Wolfe Research
$255
Buy
17.54%
Upside
Initiated
11/17/25
Ascendis Pharma initiated with an Outperform at Wolfe ResearchAscendis Pharma initiated with an Outperform at Wolfe Research
J.P. Morgan Analyst forecast on ASND
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
11/13/25
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Alkermes (NASDAQ: ALKS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush Analyst forecast on ASND
Yun Zhong
Wedbush
Wedbush
$273
Buy
25.84%
Upside
Reiterated
03/17/26
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (NASDAQ: COGT) and Ascendis Pharma (NASDAQ: ASND)
TD Cowen Analyst forecast on ASND
Yaron Werber
TD Cowen
TD Cowen
$227→$325
Buy
49.80%
Upside
Assigned
03/16/26
Ascendis Pharma: Durable Endocrine Franchise Growth and Emerging Pipeline Upside Support Buy Rating
Morgan Stanley Analyst forecast on ASND
Maxwell Skor
Morgan Stanley
Morgan Stanley
$256
Buy
18.00%
Upside
Reiterated
03/16/26
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Stevanato Group (NYSE: STVN) and BioNTech SE (NASDAQ: BNTX)
Bank of America Securities Analyst forecast on ASND
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$260→$262
Buy
20.77%
Upside
Reiterated
03/16/26
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), BioMarin Pharmaceutical (NASDAQ: BMRN) and Ionis Pharmaceuticals (NASDAQ: IONS)
Jefferies Analyst forecast on ASND
Faisal Khurshid
Jefferies
Jefferies
$290
Buy
33.67%
Upside
Initiated
03/15/26
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Plus Therapeutics (PSTV)
Cantor Fitzgerald Analyst forecast on ASND
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
$254→$300
Buy
38.28%
Upside
Reiterated
03/04/26
Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK), Ascendis Pharma (NASDAQ: ASND) and Avalo Therapeutics (NASDAQ: AVTX)
Barclays Analyst forecast on ASND
Eliana Merle
Barclays
Barclays
$342
Buy
57.64%
Upside
Reiterated
03/03/26
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Incyte (NASDAQ: INCY) and Radnet (NASDAQ: RDNT)
Stifel Nicolaus Analyst forecast on ASND
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$325→$332
Buy
53.03%
Upside
Reiterated
03/02/26
Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG), Ascendis Pharma (NASDAQ: ASND) and Roche Holding AG (Other OTC: RHHVF)
Wells Fargo Analyst forecast on ASND
Derek Archila
Wells Fargo
Wells Fargo
$330
Buy
52.11%
Upside
Reiterated
03/02/26
Wells Fargo Remains a Buy on Ascendis Pharma (ASND)
Goldman Sachs Analyst forecast on ASND
Paul Choi
Goldman Sachs
Goldman Sachs
$250→$255
Buy
17.54%
Upside
Reiterated
03/02/26
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Intellia Therapeutics (NASDAQ: NTLA) and Immunic (NASDAQ: IMUX)
RBC Capital Analyst forecast on ASND
Luca Issi
RBC Capital
RBC Capital
$250→$275
Buy
26.76%
Upside
Reiterated
03/02/26
RBC Capital Sticks to Their Buy Rating for Ascendis Pharma (ASND)
Oppenheimer Analyst forecast on ASND
Leland Gershell
Oppenheimer
Oppenheimer
$246→$262
Buy
20.77%
Upside
Reiterated
02/12/26
Oppenheimer Keeps Their Buy Rating on Ascendis Pharma (ASND)
Evercore ISI Analyst forecast on ASND
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$317
Buy
46.12%
Upside
Reiterated
01/20/26
Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (NASDAQ: ACHC) and Ascendis Pharma (NASDAQ: ASND)
Wolfe Research Analyst forecast on ASND
Unknown Analyst
Wolfe Research
Not Ranked
Wolfe Research
$255
Buy
17.54%
Upside
Initiated
11/17/25
Ascendis Pharma initiated with an Outperform at Wolfe ResearchAscendis Pharma initiated with an Outperform at Wolfe Research
J.P. Morgan Analyst forecast on ASND
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
11/13/25
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Alkermes (NASDAQ: ALKS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ascendis Pharma

3 Months
xxx
Success Rate
20/26 ratings generated profit
77%
Average Return
+10.76%
reiterated a xxx
 rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 76.92% of your transactions generating a profit, with an average return of +10.76% per trade.
1 Year
Tazeen AhmadBank of America Securities
Success Rate
30/32 ratings generated profit
94%
Average Return
+31.95%
reiterated a buy rating 15 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 93.75% of your transactions generating a profit, with an average return of +31.95% per trade.
2 Years
xxx
Success Rate
26/26 ratings generated profit
100%
Average Return
+60.87%
reiterated a xxx
 rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +60.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ASND Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
2
2
6
7
6
Buy
36
30
33
28
40
Hold
7
7
18
12
27
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
45
39
57
47
73
In the current month, ASND has received 46 Buy Ratings, 27 Hold Ratings, and 0 Sell Ratings. ASND average Analyst price target in the past 3 months is 293.77.
Each month's total comprises the sum of three months' worth of ratings.

ASND Financial Forecast

ASND Earnings Forecast

Next quarter’s earnings estimate for ASND is $0.34 with a range of -$0.36 to $0.89. The previous quarter’s EPS was -$0.64. ASND beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ASND has Performed in-line its overall industry.
Next quarter’s earnings estimate for ASND is $0.34 with a range of -$0.36 to $0.89. The previous quarter’s EPS was -$0.64. ASND beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ASND has Performed in-line its overall industry.

ASND Sales Forecast

Next quarter’s sales forecast for ASND is $321.97M with a range of $285.79M to $362.89M. The previous quarter’s sales results were $288.07M. ASND beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ASND has Performed in-line its overall industry.
Next quarter’s sales forecast for ASND is $321.97M with a range of $285.79M to $362.89M. The previous quarter’s sales results were $288.07M. ASND beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ASND has Performed in-line its overall industry.

ASND Stock Forecast FAQ

What is ASND’s average 12-month price target, according to analysts?
Based on analyst ratings, Ascendis Pharma’s 12-month average price target is 293.77.
    What is ASND’s upside potential, based on the analysts’ average price target?
    Ascendis Pharma has 35.41% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ASND a Buy, Sell or Hold?
          Ascendis Pharma has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Ascendis Pharma’s price target?
            The average price target for Ascendis Pharma is 293.77. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $342.00 ,the lowest forecast is $255.00. The average price target represents 35.41% Increase from the current price of $216.95.
              What do analysts say about Ascendis Pharma?
              Ascendis Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of ASND?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.